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Primary aldosteronism (PA) is the most common form of secondary hypertension with an 
estimated prevalence of ~10% in referred patients. PA occurs as a result of a dysregulation 
of the normal mechanisms controlling adrenal aldosterone production. It is characterized 
by hypertension with low plasma renin and elevated aldosterone and often associated 
with hypokalemia. The two major causes of PA are unilateral aldosterone producing 
adenoma (APA) and bilateral adrenal hyperplasia, accounting together for ~95% of cases. 
In addition to the well-characterized effect of excess mineralocorticoids on blood pressure, 
high levels of aldosterone also have cardiovascular, renal, and metabolic consequences. 
Hence, long-term consequences of PA include increased risk of coronary artery disease, 
myocardial infarction, heart failure, and atrial fibrillation. Despite recent progress in the 
management of patients with PA, critical issues related to diagnosis, subtype differentiation, 
and treatment of non-surgically correctable forms still persist. A better understanding of 
the pathogenic mechanisms of the disease should lead to the identification of more reliable 
diagnostic and prognostic biomarkers for a more sensitive and specific screening and 
new therapeutic options. In this review, we will summarize our current knowledge on the 
molecular and cellular mechanisms of APA development. On one hand, we will discuss 
how various animal models have improved our understanding of the pathophysiology of 
excess aldosterone production. On the other hand, we will summarize the major advances 
made during the last few years in the genetics of APA due to transcriptomic studies and 
whole exome sequencing. The identification of recurrent and somatic mutations in genes 
coding for ion channels (KCNJ5 and CACNA1D) and ATPases (ATP1A1 and ATP2B3) 
allowed highlighting the central role of calcium signaling in autonomous aldosterone 
production by the adrenal.
Keywords: primary aldosteronism, aldosterone producing adenoma, somatic mutations, potassium channels, 
calcium channels, ATPase, wnt/β-catenin pathway, shh signaling pathway
Background
Aldosterone is synthesized from cholesterol by a series of specific enzymatic reactions in the zona 
glomerulosa of the adrenal cortex; the final steps are catalyzed by the aldosterone synthase (encoded by 
CYP11B2). Aldosterone production from the adrenal cortex is tightly controlled to maintain electrolyte 
and fluid homeostasis; the two principal secretagogues are the renin/angiotensin system and the 
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extracellular concentration of potassium (K+). The stimulation by 
angiotensin II or K+ results in depolarization of the zona glomeru-
losa cell membrane and opening of voltage-gated calcium (Ca2+) 
channels, leading to an increase of intracellular Ca2+ concentration. 
Angiotensin II, by its binding to the angiotensin II type I receptor 
(AT1R), also acts by increasing inositol triphosphate formation 
leading to the release of Ca2+ from the endoplasmic reticulum. 
Activation of the calcium signaling pathway triggers a phospho-
rylation cascade, involving calmodulin and calmodulin-dependent 
kinase I/IV, leading to the activation of specific transcription fac-
tors (NURR1, NGF1B, CREB) that bind to the promoter region 
and positively regulate the transcription of CYP11B2 leading to 
an increase in aldosterone biosynthesis (Figure  1) (1). Hence, 
the activation of hormone synthesis is Ca2+ dependent, and the 
regulatory mechanism involves Ca2+ mediated processes.
Deregulation of the mechanisms regulating aldosterone biosyn-
thesis results in primary aldosteronism (PA), the most common 
form of secondary hypertension with an estimated prevalence of 
about 10% in referred patients and 4% in primary care (2) and as 
high as 20% in patients with resistant hypertension (3). PA is char-
acterized by hypertension with elevated plasma aldosterone and 
low plasma renin levels, and often associated with hypokalemia. 
The two major causes of PA are unilateral aldosterone producing 
adenoma (APA) and bilateral adrenal hyperplasia (BAH), account-
ing together for ~95% of cases. The early detection of PA has an 
important impact on clinical outcome and survival given the 
major cardiovascular adverse effect of aldosterone excess, which 
is independent of blood pressure (BP). Patients with PA have been 
reported to exhibit more severe left ventricular hypertrophy and 
diastolic dysfunction than patients with essential hypertension 
and a high prevalence of myocardial infarction, stroke, and atrial 
fibrillation (4, 5). Despite the publications in 2008 of guidelines for 
the management of PA, there remain a few critical issues related to 
diagnosis, subtype differentiation, and treatment of non-surgically 
correctable forms (6). A better understanding of the pathogenic 
mechanisms of the disease should lead to the identification of more 
reliable diagnostic and prognostic biomarkers for a more sensitive 
and specific screening and new therapeutic options.
During the last few years, major advances have been made in 
understanding the genetic basis of APA, with the identification 
of mutations in genes coding for ion channels [KCNJ5, coding 
for the G protein-activated inward rectifier potassium channel 
FiguRe 1 | Regulation of aldosterone biosynthesis in normal and 
pathological conditions. (A) Under resting conditions, zona glomerulosa 
cells exhibit a strongly negative membrane potential (−80 mV) due to the 
expression of a large number of potassium channels. (B) Stimulation of 
aldosterone biosynthesis by AngII. The binding of AngII to the AngII type I 
receptor (AT1R) induces a cascade of events leading to the zona 
glomerulosa cell depolarization and the increase of intracellular Ca2+ 
concentration. The inhibition of potassium channels and Na+, K+-ATPase by 
AngII results in zona glomerulosa cell depolarization, opening of voltage-
gated Ca2+ channels, and increase of intracellular Ca2+ concentration. 
Furthermore, activation of AT1R leads also to the increase of inositol 
triphosphate formation and consequently to the release of Ca2+ from the 
endoplasmic reticulum. Activation of the calcium signaling pathway triggers a 
phosphorylation cascade, involving calmodulin and calmodulin-dependent 
kinase I/IV, leading to the activation of specific transcription factors that bind 
to the promoter region and positively regulate the transcription of CYP11B2 
leading to an increase in aldosterone biosynthesis. (C) Genetic alterations in 
KCNJ5 (coding for the potassium channel GIRK4) and ATP1A1 (encoding the 
α1 subunit of the Na+, K+-ATPase) genes lead to cell membrane 
depolarization triggering opening of voltage-gated Ca2+ channels and 
consequently positive regulation of CYP11B2. (D) Genetic alterations in 
ATP2B3 (coding for the plasma membrane Ca2+ ATPase, PMCA3) and 
CACNA1D (encoding the Cav1.3 subunit of the L-type voltage-gated Ca2+ 
channel) genes lead directly to the increase of intracellular Ca2+ concentration 
by affecting calcium recycling and influx, resulting in positive regulation of 
CYP11B2.
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4 (GIRK4) (7) and CACNA1D, encoding the Cav1.3 channel 
(calcium channel, voltage-dependent, L type, alpha 1d subunit) 
(8, 9)] and ATPases [ATP1A1, coding for the α1 subunit of the Na+/
K+-ATPase (9, 10) and ATP2B3 encoding the plasma membrane 
Ca2+-ATPase, type 3 (10)] in more than 50% of APA. Interestingly, 
all these mutations lead to the activation of calcium signaling, the 
major trigger for aldosterone production (Figure 1). However, if 
the role of these mutations in regulating aldosterone production 
has been clearly established, their implication in proliferation and 
APA formation are still matter of debate (11).
In this review, we will summarize our current knowledge on 
the molecular and cellular mechanism of APA development. 
We will discuss how various animal models have improved our 
understanding of the pathophysiology of excess aldosterone pro-
duction. We will also summarize the major advances made during 
the last few years in the comprehension of the genetic basis of APA 
formation using omics approaches, highlighting the major role of 
the ionic equilibrium and regulation of cell membrane potential 
in autonomous aldosterone overproduction.
ionic equilibrium and Membrane Potential 
Regulation
The regulation of cell membrane potential of the zona glomerulosa 
is crucial to maintain the cell in a hyperpolarized state in the 
absence of a secretagogue stimulus. The zona glomerulosa cell 
membrane is selectively permeable to K+, giving it the charac-
teristics of a K+ electrode over a wide range of extracellular K+ 
concentrations, due to the expression of a large number of potas-
sium channels. However, their major role in the development of 
APA was highlighted only recently by the identification of somatic 
and germline mutations in genes coding for proteins involved in 
ionic equilibrium and membrane potential regulation but also 
by the establishment and analysis of mouse models in which the 
expression of specific potassium channels was invalidated.
Alteration of ionic equilibrium in APA
In 2011, by a whole exome sequencing approach, few recurrent 
somatic KCNJ5 mutations were identified (7). These mutations 
(p.Gly151Arg and p.Leu168Arg) are located near or within the 
selectivity filter of the channel GIRK4. Additional mutations in or 
surrounding the selectivity filter have been identified, including 
p.Gly151Glu, p.Thr158Ala, p.Glu141Gln, p.Ile157Ser, delIle157, 
InsThr149 (12–16). All these mutations result in a significant 
decrease in K+ selectivity and greater influx of Na+ into the cell, 
resulting in chronic cell depolarization followed by opening of 
voltage-dependent calcium channels and activation of calcium 
signaling and aldosterone production (11, 17). Germline KCNJ5 
mutations were also identified as the causative event of Familial 
hyperaldosteronism type III (FH-III). FH-III was first described in 
2008 in a father and two daughters with early-onset severe arterial 
hypertension resistant to medical treatment and hypokalemia (18). 
To control BP, a bilateral adrenalectomy was required for all three 
individuals; histology revealed massive hyperplasia of the adrenal 
cortex (18). Further exome sequencing performed on APA allowed 
the identification of other somatic mutations in genes coding for 
ATPases, namely ATP1A1 (9, 10) and ATP2B3 (10) and the Cav1.3 
calcium channel, CACNA1D (8, 9). Whereas mutations in KCNJ5 
and ATP1A1 affect adrenal zona glomerulosa cell membrane poten-
tial and intracellular ionic homeostasis, with chronic depolariza-
tion leading to opening of voltage-dependent calcium channels 
and activation of calcium signaling and aldosterone production 
(7, 9–11), mutations in ATP2B3 and CACNA1D modify directly 
intracellular calcium equilibrium, also leading to an activation of 
calcium signaling and aldosterone production (Figure 1) (8–10).
Prevalence of Somatic Mutations and genotype/
Phenotype Correlations
The prevalence of somatic mutations in APA has been extensively 
investigated in many studies (9, 10, 14, 19–22). KCNJ5 mutations 
are the most frequent genetic abnormalities reported in APA with 
a prevalence of ~40% in Caucasian population, and as high as 70% 
in series from Japan (21, 23). The mutations affecting ATP1A1 
and ATP2B3 genes are less frequent with a reported prevalence of 
5.3 and 1.7, respectively (9, 10, 20). Mutations in the CACNA1D 
gene are the second most frequent genetic alterations observed 
in APA with a prevalence comprised between 5 and 9.3% (8, 9, 
20). Interestingly, whereas mutations in KCNJ5, ATP1A1, and 
ATP2B3 are located in specific “hot spots,” a large number of 
mutations were reported in different exons of the CACNA1D gene, 
affecting more frequently segment M4 and M6 of the protein, 
implying the necessity of a large genotyping of CACNA1D in 
APA. Different studies established correlations between clinical 
and biological parameters and the mutational status of the tumor 
(10, 19, 20). Hence, patients with KCNJ5 mutations were more 
frequently female and diagnosed younger than patients harbor-
ing CACNA1D mutations and non-carriers (20); and CACNA1D 
mutations associated with smaller adenoma size (9, 20). Some 
studies reported also association between the mutational status 
and cellular composition of the adenoma. APA harboring KCNJ5 
mutations would be composed essentially of zona fasciculata-like 
cells whereas those carrying CACNA1D mutations of a majority 
of zona glomerulosa-like cells (9), although this association was 
not replicated in all series (20). The exploration of the relationship 
between adrenal cortex remodeling and KCNJ5 mutations revealed 
the absence of association between the KCNJ5 mutational status 
and the nodulation score in the peritumoral tissue, the vascu-
larization and the presence of zona glomerulosa hyperplasia in 
the peritumoral cortex, suggesting that KCNJ5 mutations are not 
likely to be responsible for a specific microenvironment propitious 
to promote adrenal cortex remodeling and APA formation (24).
Lessons from Potassium Channel Knock-Out 
Mouse Models
Though the role of all these mutations in abnormal aldosterone 
secretion has been clearly established, their impact in adenoma 
formation still remains unclear. Indeed, whereas in HAC15 cells, 
the overexpression of GIRK4 carrying the p.Thr158Ala mutation 
was responsible for a significant increase in aldosterone produc-
tion, it induced, in parallel, a decrease in cell proliferation, inde-
pendently of intracellular Ca2+ concentration (11). Likewise, the 
overexpression of p.Glu151Arg or p.Glu151Gln in HEK293T cells 
resulted in rapid Na+-dependent lethality (15). More extensively, a 
still open question is to know whether a modification in the ionic 
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equilibrium and the regulation of the cell membrane potential 
are also able to promote adenoma formation. Response elements 
came some years ago with the investigation of mouse models in 
which TASK1 and/or TASK3 potassium channels were invalidated 
to determine the contributions of TASK channels to background 
K+ currents in adrenal zona glomerulosa cells and test their role in 
the control of aldosterone production (25, 26). TASK1 and TASK3 
are two-pore domain K+ channels (K2P) that contribute largely 
to the very high background conductance of zona glomerulosa 
cells, making of zona glomerulosa cells highly sensitive sensor 
for plasma K+ concentration. They clamp the cell membrane to 
hyperpolarized voltages, restraining the production of aldosterone 
in absence of stimulus. In mouse adrenal cortex, whereas TASK1 
expression is found throughout the zona glomerulosa and fas-
ciculata, TASK3 expression is restricted to zona glomerulosa (25). 
Deletions of task1 and task3, respectively, lead to the development 
of hyperaldosteronism or low-renin hypertension (25–28) In 
task1−/− mice, hyperaldosteronism was due to aberrant functional 
zonation of the adrenal cortex, with intense cyp11b2 expression 
being localized in zona fasciculata instead of the zona glomerulosa. 
Interestingly, young task1−/− mice exhibited PA both in males 
and females; after puberty, this phenotype was only observed in 
females. Hyperaldosteronism was modulated by sexual hormones, 
being corrected by testosterone administration in task1−/− females 
and triggered by castration in males (26), suggesting that after 
puberty other factors, including task3 potassium channels, could 
substitute for the absence of task1 and promote compensatory 
mechanisms in male task1−/− mice (26). Deletion of task3 in mice 
leads to low-renin salt-sensitive hypertension, with suppressed 
plasma renin and aldosterone secretion that is not suppressible 
by increasing salt intake (27). Primary cultures of adrenocortical 
cells of these mice were strongly depolarized when compared with 
wild-type mice, and in fresh adrenal slices, calcium signaling was 
abnormal in zona glomerulosa cells (28). Finally, deletion of both 
task1 and task3 results in a marked depolarization of the zona 
glomerulosa cell membrane potential and a mild hyperaldosteron-
ism with plasma aldosterone levels stimulated by a low-sodium diet 
but not suppressed by a high-sodium diet and partially responsive 
to AngII blockade (25). Interestingly, invalidation of these different 
potassium channels leads to hyperaldosteronism due to abnormal 
depolarization of the zona glomerulosa cell membrane resulting 
in increased intracellular Ca2+ concentration and stimulation of 
aldosterone biosynthesis; however formation of adrenal tumors 
has never been observed in these models indicating that other 
mechanisms are required to promote increased cell proliferation 
in APA. Although the invalidation of task1 and task3 in mice 
resulted in hyperaldosteronism or low-renin hypertension, to date 
no mutation in KCNK3 or KCNK9 genes has been reported in APA. 
However a reduced expression of TASK2, encoded by KCNK5, has 
been recently described in APA compared with normal adrenal 
(29), and the expression in H295R cells of a TASK2 dominant-
negative mutant resulted in increased aldosterone production and 
CYP11B2 and StAR expression. Comparison of gene expression 
profiles of adrenal glands of task1−/− female and male mice allowed 
the identification of a cluster of genes closely associated with hyper-
aldosteronism (30), among them dickkopf3 (Dkk3), a member of 
the dickkopf family of Wnt signaling modulators. Inactivation of 
dkk3 in task1−/− mice resulted in the extension of the phenotype of 
hyperaldosteronism to male animals, without inducing abnormal 
zonation of the adrenal cortex (30). Interestingly, the expression 
of Dkk3 was found to be frequently downregulated in almost 
any cancer entity and emerged as a potential key player in tumor 
suppression (31). These results suggest that the Wnt/β-catenin 
pathway could play a role in the development of APA.
Activation of Sonic HedgeHog and wnt/ 
β-Catenin Pathway: Common Features of 
APA
The role of specific mutations of channels and ATPases in affecting 
aldosterone biosynthesis is now clearly established, whereas the 
question of the mechanism responsible for abnormal proliferation 
leading to adenoma formation is still open. In 2011, Lifton suggested 
that KCNJ5 mutations could be responsible for both autonomous 
aldosterone production and abnormal cell proliferation (7); however 
it has been rapidly shown that cells expressing mutated KCNJ5 chan-
nels were less proliferative (11), raising the questions as to the events 
leading to abnormal cell proliferation and adenoma formation? 
Two specific pathways are known to play a crucial role in adrenal 
development: the Sonic HedgeHog and the Wnt/β-catenin pathways.
wnt Signaling Pathway in Proliferation and/or 
Aldosterone Biosynthesis
The Canonical and Non-Canonical Wnt/β-Catenin Pathway
Wnt signaling has been shown to be a key signaling pathway 
in both normal adrenal development and tumorigenesis. The 
“canonical Wnt signaling pathway” acts through the regulation 
of the amount of the transcriptional regulator β-catenin, which 
controls the expression of specific genes involved in development. 
In the absence of Wnt, β-catenin is a part of the axin complex 
consisting of adenomatous polyposis coli (APC), axin, glycogen 
synthase kinase-3β (GSK-3β), and casein kinase-1β (CK-1β). 
CK-1β and GSK-3β sequentially phosphorylate β-catenin in its 
N-terminal part resulting in its ubiquitination and degradation 
by the proteasome, thus preventing β-catenin from translocation 
to the nucleus and activation of specific Wnt target genes. The 
Wnt/β-catenin activation occurs through the binding of Wnt 
ligand to its cell surface receptor consisting of a frizzled receptor 
and its co-receptor, the low-density lipoprotein receptor related 
protein (LRP) 6 or LRP5. Activation of the receptor leads, through 
an unknown mechanism, to the phosphorylation of the disheveled 
(Dvl) protein, which prevents GSK-3β from phosphorylating 
specific substrates such as axin, APC, and β-catenin. Hence, the 
binding of Wnt ligands to their receptor results in the inhibition 
of β-catenin phosphorylation, dissociation from the axin complex, 
accumulation in the cytoplasm and translocation to the nucleus 
where it serves as a transcriptional coactivator of transcription 
factors of the T-cell factor (TCF)/lymphocyte enhancer factor 
(LEF) family. TCF/LEF target genes are involved in regulating 
cell proliferation, stem cells maintenance, and differentiation. To 
increase the complexity of the system, Wnt signaling independent 
of β-catenin has been described as “non-canonical Wnt signaling 
pathway.” It implicates small GTPases/jun N-terminal kinase 
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(JNK) and intracellular calcium signaling (32). Finally, the activa-
tion of the Wnt pathway can be antagonized by specific natural 
molecules including secreted Frizzled-related proteins (sFrps) and 
Dickkopk (Dkk) family members. SFrps and Dkk are secreted 
proteins acting on different components of the Wnt signaling 
pathway. sFrps display a high sequence homology with the Wnt 
binding site of Frizzled allowing sFRP proteins to directly bind to 
Wnts, thus functioning as Wnt antagonists for both “canonical” 
and “non-canonical” pathways (33), whereas Dkk members are 
not only able to inhibit the Wnt coreceptors LRP5 and 6 but also 
to bind with high affinity to the transmembrane proteins Kremen 
1 and 2, which also modulate Wnt signaling (33, 34).
Role of Wnt/β-Catenin Pathway in Adrenal Function
The Wnt/β-catenin pathway plays an important role in embryonic 
development, stem cell maintenance, and differentiation in many 
tissues. During the two last decades, the role of Wnt/β-catenin 
in adrenal development has been highlighted by the exploration 
of different mouse models in which expression of different com-
ponents of the pathway were disrupted (35–37) or constitutively 
activated (38). The first element indicating a role of this pathway in 
adrenal is the localization of some of its components (i.e., β-catenin, 
wnt4, dkk3, sfrp1…) specifically in the subcapsular zone and in 
zona glomerulosa (39, 40). The loss of Wnt4 was associated with 
abnormal differentiation of the definitive zone of the adrenal cortex 
and aberrant migration of adrenocortical cells into the developing 
gonad (35) and with a decrease of the number of zona glomerulosa 
cells which results in a decrease of aldosterone production (36). 
Interestingly, the expression of Wnt4 mRNA has been reported to 
be higher in APA than in normal adult adrenocortical cells (41). 
Overexpression of WNT4 in human adrenocortical cells resulted 
in an increase of aldosterone biosynthesis, whereas DKK3 had an 
inhibitory effect, suggesting that Wnt/β-catenin pathway could be 
also involved in glomerulosa specific functions (42).
Modulation of β-Catenin Expression or Activation in the 
Adrenal Gland
The disruption of β-catenin specifically in adrenocortical cells, 
through the use of a sf-1 (steroidogenic factor-1)-Cre mouse, resulted 
in complete adrenal aplasia or defects in maintenance of the adult 
cortex resulting in depletion of adrenocortical cells (37). Inversely, 
the constitutive activation of β-catenin in the adrenal cortex resulted 
in profound adrenocortical zonation defects characterized by an 
ectopic activation of the zona glomerulosa differentiation program 
and inhibition of orthotopic zona fasciculata differentiation. 
Interestingly, at the age of 10 months, these mice develop hyperal-
dosteronism (38) similarly to mice expressing a defective APC allele 
(43), suggesting that constitutive activation of the Wnt/β-catenin 
pathway could play a role in the development of APA. In human 
adrenal, while β-catenin expression was found in the entire cortex, 
its activated form was restricted to zona glomerulosa cells (44), 
suggesting that restriction of β-catenin activation to sub-capsular 
regions and in zona glomerulosa is necessary for the development of 
functional zonation in the human adrenal cortex. Studies in human 
adrenocortical cells have indicated that Wnt signaling molecules 
may also have multiple actions on steroidogenesis, particularly in 
regulating aldosterone biosynthesis (36, 45). All these results suggest 
that aberrant Wnt signaling may be driving the development of 
APA. Recently, the activation of Wnt/β-catenin has been reported 
in two-thirds of APA (44, 46). Whereas activating mutations of the 
β-catenin are found in a wide variety of human cancers including 
adrenocortical tumors and adrenocortical adenoma, only few 
mutations were reported in APA (8, 47) strongly suggesting that 
the activation of β-catenin was not associated with the presence 
of mutation (47–49). Moreover, in adrenocortical carcinoma, the 
activation of β-catenin was associated with a poor prognosis (49), 
whereas in APA it was not associated with specific tumor character-
istics. Thus Wnt/β-catenin activation may play distinct roles in APA 
compared to adrenal cortex carcinoma, contributing to aldosterone 
hypersecretion rather than to autonomous cell proliferation (46). 
The activation of β-catenin was not only associated with an increased 
expression of specific target genes, i.e., AXIN2 and LEF1, but also 
with down regulation of SFRP2, a member of the SFRP family of 
Wnt signaling inhibitors (46). Interestingly, sfrp2 knockout mice 
exhibit an increase in plasma aldosterone concentration, associated 
with ectopic expression of cyp11b2 in adrenal cortex, similarly to 
what observed in mice expressing the constitutive active form of 
β-catenin in adrenal cortex (46).
Shh Signaling Pathway in APA
Similarly to the Wnt/β-catenin signaling pathway, Sonic HedgeHog 
signaling (shh) is essential for adrenal gland development and 
maintenance. Shh encodes a secreted signal that belongs to the 
Hedgehog family. The activation of shh signaling occurs through 
its binding to a receptor complex formed by the twelve trans-
membrane domain protein patched-1 (PTCH1) and the G-protein 
coupled receptor Smoothened (SMO). In the presence of Shh, SMO 
is released from PTCH1 inhibition and activates the transcription 
factors GLI1, GLI2, and GLI3 (50). In rodent adult adrenals, Shh is 
expressed exclusively in the subcapsular region of the cortex in cells 
also expressing sf1, indicating their commitment to steroidogenic 
cells (51–53). Similarly, in human adult adrenals, the expression 
of SHH was found to be restricted to a few numbers of cells of the 
subcapsular region, where stem/progenitor cells are supposed to 
be localized (44, 54). Mice invalidated for Shh, specifically in Sf1 
positive cells, exhibit reduced proliferation of capsular cells and a 
significant reduction of adrenocortex thickness and adrenal size 
but no modification of adrenal zonation. Moreover, the remaining 
adrenal cortex was able to synthetize steroids, indicating that shh is 
essential for expansion of the adrenal cortex but not for zonation 
and differentiation (55). Interestingly, the expression of Shh was 
found in APA as well as in the entire hyperplasic zona glomerulosa, 
with a similar pattern of expression than CYP11B2 and Dab2 
(44). The activation of the SHH signaling pathway in APA was 
confirmed by transcriptomic analysis (44). These results suggest 
that APA have acquired some characteristics of stem/precursor 
cells or, alternatively, that reexpression of fetal markers from the 
definitive zone in the adrenal cortex could underlie excessive 
proliferation and APA formation. Remarkably, the antagonism of 
hedgehog signaling has been shown to inhibit the proliferation 
of H295R cells (56) and to decrease cell viability (57). Moreover, 
the inhibition of shh signaling pathway results in the inhibition of 
wnt/β-catenin signaling (57). Interestingly, the activation of shh 
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signaling pathway was found to be increased in adult adrenocorti-
cal carcinoma (57) as well as in non-producing adenoma (56), 
suggesting a role in tumor formation or development.
Clock genes in the Control of Aldosterone 
Production
Many physiological functions such as metabolism, BP, and renal 
function are regulated by the circadian clock (58–60). Up to 10% 
of the transcriptome has been estimated to be under the control 
of the circadian clock and a number of diseases are associated 
with clock gene disorders (61). The circadian timing system is 
organized in central and peripheral clocks. The central circadian 
clock is composed of specialized neurons in suprachiasmatic 
nuclei in the hypothalamus and is synchronized to the daily 
light/dark cycle through the retino-hypothalamic tract (62). The 
peripheral circadian clocks, found in most peripheral tissues, 
are synchronized to geophysical time through a wide range of 
master clock-dependent stimuli (62, 63). Four canonical proteins 
are the components of the circadian time clocks: period (Per)1–3, 
cryptochrome (Cry)1–2, Bmal1, and Clock. Clock and Bmal1 form 
a heterodimer that interacts with E-boxes to transcriptionally 
upregulate clock-controlled genes, which include Per and Cry 
(62, 64). Cry proteins act as potent transcriptional repressors that 
downregulate the transcription of E-box (CACGTG) enhancer-
containing clock genes (including Per- and Cry-encoding genes) 
as well as a wide variety of clock-controlled genes (65, 66).
Different circadian mutant mice models show abnormalities 
in BP regulation and/or plasma aldosterone concentration. BP 
is decreased in clock knockout mice, accompanied by changes in 
circadian rhythms of urinary sodium and potassium excretion, 
and loss of the circadian rhythmicity of plasma aldosterone (67). 
A mouse model carrying a conditional allele of the circadian 
clock gene Bmal1 and expressing Cre recombinase under the 
endogenous Renin promoter (Bmal1lox/lox/Ren1dCre) loose the 
BMAL1 protein expression in the renin-secreting granular cells of 
the juxtaglomerular apparatus. These mice exhibit decreased BP, 
increased urine volume, changes in the circadian rhythm of urinary 
sodium excretion, and significantly reduced plasma aldosterone 
(63). Mice lacking the core clock components Cry1 and Cry2 
(referred as Cry-null mice) show disrupted rhythmic behavior, 
physiology, and metabolism (68, 69). Interestingly, Cry-null mice 
exhibit salt-sensitive hypertension due to increased aldosterone 
production by the adrenal gland (70). Investigation of steroido-
genic alterations in Cry-null mice showed chronic overexpression 
of Hsd3b6 mRNA and chronically enhanced 3β-hydroxysteroid 
dehydrogenase activity in adrenal cortex. Hsd3b6 encodes a 
dehydrogenase-isomerase specifically expressed in zona glo-
merulosa, which catalyzes the conversion of pregnenolone into 
progesterone, an enzymatic reaction required for aldosterone 
biosynthesis. The inactivation of Cry genes leads to chronically 
enhanced mineralocorticoid production, which, in turn, renders 
BP salt sensitive (70). On the other hand, it has been previously 
shown that Per1 and Cry2 modulate opposing actions on Per1 target 
gene expression in some tissues (71). Remarkably, Per1 knockout 
mice exhibit lower BP when compared to wild-type mice (60). To 
verify the hypothesis that Per1 plays a role in the regulation of aldos-
terone levels, Richards et al. have performed RNA silencing and 
pharmacological blockade of Per1 nuclear entry in the NCI-H295R 
human adrenal cell line, demonstrating that Hsd3b6 expression is 
decreased after Per1 knockdown in vitro (72). In addition, they 
have demonstrated that Per1 heterozygous mice exhibited lower 
plasma aldosterone levels and reduced Hsd3b6 mRNA expression 
in vivo, with a significant blunted circadian expression of this gene 
(72). In the human adrenal, two 3β-hydroxysteroid dehydrogenase 
isoform are expressed, namely HSD3B1 and HSD3B2 (70). In 
the adrenal cortex, expression of HSD3B1 is specific to the zona 
glomerulosa (70), suggesting its potential involvement in adrenal 
zona glomerulosa pathophysiology. Both HSD3B1 and HSD3B2 
are found to be express in APA; and whereas HSD3B2 expression 
was higher than that of HSD3B1 in APA, only the level of HSD3B1 
expression was correlated with plasmatic aldosterone concentration 
and CYP11B2 expression in APA, suggesting that HSD3B1 may 
contribute to autonomous aldosterone production in APA (73).
Conclusion
Despite major advances performed these last years in our under-
standing of the pathophysiology of APA development, the natural 
history of APA formation is still a matter of debate. Our current 
knowledge is not enough advanced to explain the mechanisms 
involved in APA formation. However, the identification, in about 
50% of APA, of recurrent somatic mutations in genes coding for 
ionic channels and ATPases has elucidated the mechanism respon-
sible for the autonomous aldosterone production. On the other 
hand, activation of the Wnt/β-catenin pathway or reexpression of 
stem/precursor cell markers, i.e., shh, could explain the abnormal 
proliferation leading to the formation of an adenoma. It is possible 
that APA formation is the result of the combination of two events: 
(1) the activation of signaling pathways such as wnt/β-catenin or 
shh pathways driving abnormal cell proliferation and creating a 
favorable environment for (2) the occurrence of recurrent somatic 
mutations responsible for autonomous aldosterone production.
Although it was suggested that genetic alterations leading 
to abnormal calcium signaling are sufficient for both abnormal 
proliferation and inappropriate aldosterone production in APA, 
there are some evidences suggesting that mutations in potas-
sium and calcium channel and ATPases may not be sufficient 
for promoting cell proliferation and tumor formation. It could 
be speculated that some groups of cells start to abnormally pro-
liferate creating a propitious environment for the emergence of 
specific mutations affecting ionic channels and ATPases leading 
to increased aldosterone production. Further mechanistic insight 
may come from specific mouse models developing a phenotype of 
hyperaldosteronism in the context of an APA.
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